PTGS2 and neoplasm: Of course, it cannot be ruled out that, as with celecoxib, the reduction in IDO activity and inhibition of tumor growth may result from COX-2 inhibition, but this points to the potential utility of other COX-2 inhibitors to control IDO activation in cancer treatment [138,139,149].